Pulmonary alveolar proteinosis during treatment of immune-mediated necrotizing myopathy

Int J Rheum Dis. 2024 Feb;27(2):e15080. doi: 10.1111/1756-185X.15080.

Authors

Naofumi Dobashi^{1

2

3

4}, Ken-Ei Sada^{1

2}, Gen Kanemori³, Takuya Okada^{3

4}, Yusuke Tarutani^{3

4}, Mako Yamamoto^{3

4}, Moemi Yabe^{3

4}, Kenshi Inoue^{3

4}, Yasuhiko Imaizumi^{3

4}, Masahiko Nishii⁵, Masahiro Katsurada⁵, Kenta Misaki^{3

4}

Affiliations

¹ Department of Internal Medicine, Kochi Prefectural Hata-Kenmin Hospital, Sukumo, Japan.
² Department of Clinical Epidemiology, Kochi Medical School, Kochi University, Nankoku, Japan.
³ Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan.
⁴ Rheumatology Center, Kita-Harima Medical Center, Hyogo, Japan.
⁵ Department of Oncology Respiratory Medicine, Kita-Harima Medical Center, Hyogo, Japan.

PMID: 38339847
DOI: 10.1111/1756-185X.15080

No abstract available

Publication types

Letter

MeSH terms

Autoimmune Diseases* / diagnosis
Autoimmune Diseases* / drug therapy
Humans
Lung
Myositis*
Pulmonary Alveolar Proteinosis* / diagnosis
Pulmonary Alveolar Proteinosis* / drug therapy